Recruiting Clinical Trials

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas

By April 24, 2017 No Comments



Estimated Enrollment: 36

Age Group: 18 Years to 80 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Other

Study ID Numbers: H-36460

Study First Received: July 16, 2016

Last Updated: March 24, 2017

Estimated Primary Completion Date: July 2018


Primary Outcome Measures:

Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.

Sponsors and Collaborators:

Baylor College of Medicine

Website Link:

Leave a Reply

Call Now ButtonCall Now